Comparison of Clinical Efficacy between Peritoneal Dialysis and Hemodialysis in the Treatment of Diabetic Nephropathy

2021 ◽  
2018 ◽  
Vol 19 (1) ◽  
pp. 89-91
Author(s):  
Dejan Pilcevic

AbstractPeritonitis remains a major complication of peritoneal dialysis which is usually caused by saprophytic gram positive microorganisms originated from skin. Here, I report an unusual case of peritonitis due to Moraxella catarrhalis.A male, 59 age, on peritoneal dialysis modality because ESRD due to diabetic nephropathy was admitted to our hospital due to CAPD peritonitis. After initial empiric treatment and identification of this infrequent causer, he was submitted to two week antibiotic treatment with complete recovery and good prognosis.Peritonitis is the major cause of peritoneal dialysis failure which requires prompt recognition of the causative agent for successful treatment.


BMJ ◽  
1976 ◽  
Vol 1 (6001) ◽  
pp. 93-93
Author(s):  
M J Blumenkrantz ◽  
J E Bailey ◽  
M Yaron ◽  
J W Cburn

2020 ◽  
Vol 36 (7) ◽  
Author(s):  
Xiao-dong Xu ◽  
Xue Han ◽  
Yi Yang ◽  
Xu Li

Objective: Diabetic nephropathy is a serious threat to human health, and its incidence is on the rise. End-stage diabetic nephropathy (ESDN) requires extra investigation due to its complexity and severity, as well as serious concurrent diseases. Our objective was to compare the efficacy of hemodialysis (HD) and peritoneal dialysis (PD) in the treatment of ESDN. Methods: Clinical data of 84 patients with ESDN admitted to our hospital from June 2016 to June 2018 were retrospectively analyzed. The patients were divided into an HD group that received hemodialysis and a PD group that received peritoneal dialysis. Their general conditions, biochemical indicators, residual renal function and incidence of complications were recorded and compared between the two groups. Results: (1) No significant difference in diastolic blood pressure, systolic blood pressure, body weight, or urine output was detected between the two groups at the beginning of dialysis (P>0.05). (2) Compared to the PD group, the HD group had significantly lower total cholesterol (TC) and triglyceride (TG) (P<0.05), and significantly higher total protein (TP) and albumin (ALB) after treatment (P<0.05). (3) The two groups also showed significant difference in residual renal function after treatment (P<0.05). (4) The HD group had significantly higher systolic pressure than the PD group after treatment (P<0.05). And more cases of infection were observed in the PD group than the HD group (P<0.05). Conclusion: Both HD and PD are used for treatment of ESDN, and can achieve similar calcium and phosphorus control. Compared to HD, PD has less adverse effect on hemodynamics and better preserves residual renal function, but is more likely to cause malnutrition and disorders of lipid metabolism. Therefore, choice of dialysis method should be based on specific conditions of each patient. doi: https://doi.org/10.12669/pjms.36.7.2901 How to cite this:Xu XD, Han X, Yang Y, Li X. Comparative study on the efficacy of peritoneal dialysis and hemodialysis in patients with end-stage diabetic nephropathy. Pak J Med Sci. 2020;36(7):---------. doi: https://doi.org/10.12669/pjms.36.7.2901 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


2020 ◽  
Author(s):  
Xiaoying Ma ◽  
HaiPing Xu ◽  
FuYun Sun

Abstract Background: This study aimed to analyze the characteristics, outcomes and prognosis factors of survival in elderly peritoneal dialysis patients, so as to better understand the status of elderly peritoneal dialysis patients and improve their quality of life.Methods: This study was a prospective, observational study that included peritoneal dialysis (PD)patients.Categorizing by age, elderly group aged ≥ 65, younger group aged < 65. Clinical characteristics, survival and transferring to hemodialysis were compared between two groups.Meanwhile, risk factors for death in elderly PD patients were explored.Results: A total of 202 PD patients were enrolled, including 61 in elderly group and 141 in younger group. Among elderly individuals,serum albumin and normalized protein catabolic rate(nPCR) decreased, the incidence of previous cardiovascular, cerebrovascular diseases and Charlson Comorbidity Index(CCI) were higher.The major primary disease in elderly patients was diabetic nephropathy, significant differences were found between elderly and younger group(P < 0.01). The mortality in elderly group was substantially higher, 27 patients (44.3%) died in elderly group and 21 patients(14.3%) died in younger group .The 1-year,2-year,3-year,4-year survival rate were 81.97%, 70.49%, 60.66%, 55.74% respectively. Cardiovascular disease was the main cause of death in elderly PD patients. Higher BMI, CCI, and previous ischemic heart disease were risk factors for long-term survival of elderly PD patients. Compared with the younger group, elderly patients were less likely to transfer to hemodialysis: 2 cases (3.3%) in elderly group and 23 cases (16.3%) in younger group. Peritonitis was the primary reason for converting to hemodialysis(HD) in both two groups.Conclusions: Poor nutrition, more complications and diabetic nephropathy were characteristics of elderly PD patients. High BMI, CCI and previous ischemic heart disease were independent predictors of death in elderly PD patients. Cardiovascular disease was the main cause of death in elderly PD patients,while the chief reason of transferring to hemodialysis was peritonitis.


2020 ◽  
Author(s):  
Xiaoying Ma ◽  
HaiPing Xu ◽  
FuYun Sun

Abstract Background This study aimed to analyze the characteristics, outcomes and prognosis factors of survival in elderly peritoneal dialysis patients, so as to better understand the status of elderly peritoneal dialysis patients and improve their quality of life.Methods This study was a prospective, observational study that included peritoneal dialysis (PD)patients.Categorizing by age, elderly group is aged ≥ 65, younger group is aged < 65. Clinical characteristics, survival and transferring to hemodialysis were compared between two groups.Meanwhile, risk factors of death in elderly PD patients were explored.Results A total of 202 PD patients were enrolled, including 61 in elderly group and 141 in younger group. The comparison of baseline data between two groups: in elderly group serum albumin and normalized protein catabolic rate(nPCR) decreased, the incidence of previous cardiovascular and cerebrovascular diseases and Charlson Comorbidity Index(CCI) were higher, the major primary disease in elderly patients was diabetic nephropathy, significant differences were found between elderly and younger group(P < 0.01). The mortality in elderly group was substantially higher, 27 patients (44.3%) died in elderly group and 21 patients(14.3%) died in younger group .The 1-year,2-year,3-year,4-year survival rate were 81.97%, 70.49%, 60.66%, 55.74%,respectively. Cardiovascular disease was the main cause of death in elderly PD patients. Higher BMI 、CCI, and previous ischemic heart disease(IHD)were risk factors for long-term survival of elderly PD patients. Compared with the younger group, elderly patients were less likely to transfer to hemodialysis: 2 cases (3.3%) in elderly group and 23 cases (16.3%) in younger group. Peritonitis was primary reason for converting to hemodialysis(HD) in both two group.Conclusions Poor nutrition, more complications and diabetic nephropathy were characteristics of elderly PD patients. High BMI, CCI and previous IHD were independent predictors of death in elderly PD patients. Cardiovascular disease was the main cause of death in elderly PD patients,while the chief reason of transferring to hemodialysis was peritonitis.


Open Medicine ◽  
2016 ◽  
Vol 11 (1) ◽  
pp. 611-617 ◽  
Author(s):  
Yan Hong ◽  
Zhihong Gui ◽  
Xiaoping Cai ◽  
Lejian lan

AbstractThe aim of this meta-analysis was to evaluate the clinical efficacy and safety of tripterygium glycosides in treatment of stage IV diabetic nephropathy. Methods Through searching the PubMed and CNKI databases, the open published clinically controlled trials related to efficacy and safety of tripterygium glycosides in the treatment of stage IV diabetic nephropathy were collected. The pooled total efficacy, 24h urinary protein, serum creatinine and tripterygium glycosides related toxicity were calculated using Stata 11.0 software. Results Fourteen publications including 992 subjects (512 in the experimental group and 480 in the control group) were included in this study. Eight studies reported the total clinical efficacy comparing the experiment and control groups. No significant statistical heterogeneity was found in total efficacy (I2=24.9%, p>0.05). Thus, the combined odds ratio (OR) was pooled by fixed effect model. The pooled OR=4.16 with its 95% CI 2.71~6.37 (p<0.05), which indicated the total efficacy in the experiment group, was significant higher than that of control group (p<0.05); Thirteen studies reported the post-treatment 24h urinary protein value. Statistical heterogeneity analysis indicated significant heterogeneity across studies (I2=91.1%, p<0.05); that data was pooled by a random effects model. The combined standardized mean difference (SMD) was -1.55 with its 95% I -2.06~1.03, (p<0.05). The results indicated that post-treatment 24h urinary protein in the experiment group was significant lower than that in control group (p<0.05); Ten studies reported the post-treatment serum creatinine. Significant heterogeneity existed across those studies (I2=82.3%, p<0.05). Thereafter, the data was pooled by a random effect model. The combined standardized mean difference (SMD) was −0.24 with its 95%CI −0.40~0.09, (p<0.05). The results indicated that the post-treatment serum creatinine in experiment group was significant lower than that of control group (p<0.05); Eight studies reported tripterygium glycoside-associated toxicity such as liver function damage, gastrointestinal reactions and menstrual disorders. With no statistical heterogeneity among the studies, the data was pooled by fixed effect model. The pooled OR=6.42 (95%CI 2.23~18.48, p<0.05). The pooled results showed the tripterygium glycoside- associated toxicity incidence rate was significant higher in the experiment group than that of the control group (p<0.05); There were no publication bias for effect size of total efficacy, 24h urinary protein, and serum creatinine. However, for tripterygium glycoside-related toxicity, the publication bias was significant (t=-3.55, p<0.05). Conclusion The present evidence shows that tripterygium glycosides can improve clinical efficacy, reduce the 24h urinary protein and serum creatinine, but that they increase the tripterygium glycoside-related toxicity in treatment of stage IV diabetic nephropathy.


Sign in / Sign up

Export Citation Format

Share Document